Logo image of AGFB.BR

AGFA-GEVAERT NV (AGFB.BR) Stock Fundamental Analysis

EBR:AGFB - BE0003755692 - Common Stock

0.983 EUR
-0.03 (-3.25%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, AGFB scores 3 out of 10 in our fundamental rating. AGFB was compared to 11 industry peers in the Health Care Technology industry. While AGFB seems to be doing ok healthwise, there are quite some concerns on its profitability. AGFB has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AGFB has reported negative net income.
AGFB had a positive operating cash flow in the past year.
In the past 5 years AGFB reported 4 times negative net income.
In the past 5 years AGFB always reported negative operating cash flow.
AGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFAGFB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

1.2 Ratios

AGFB's Return On Assets of -6.69% is on the low side compared to the rest of the industry. AGFB is outperformed by 63.64% of its industry peers.
AGFB has a worse Return On Equity (-31.51%) than 63.64% of its industry peers.
Industry RankSector Rank
ROA -6.69%
ROE -31.51%
ROIC N/A
ROA(3y)-8.91%
ROA(5y)0.06%
ROE(3y)-32.3%
ROE(5y)1.63%
ROIC(3y)N/A
ROIC(5y)N/A
AGFB.BR Yearly ROA, ROE, ROICAGFB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

AGFB's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 31.24%, AGFB is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
AGFB's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for AGFB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.24%
OM growth 3Y-1.64%
OM growth 5Y-16.64%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.88%
AGFB.BR Yearly Profit, Operating, Gross MarginsAGFB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

4

2. Health

2.1 Basic Checks

AGFB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGFB remains at a similar level compared to 1 year ago.
The number of shares outstanding for AGFB has been reduced compared to 5 years ago.
Compared to 1 year ago, AGFB has a worse debt to assets ratio.
AGFB.BR Yearly Shares OutstandingAGFB.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
AGFB.BR Yearly Total Debt VS Total AssetsAGFB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 2.15 indicates that AGFB is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.15, AGFB is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
A Debt/Equity ratio of 0.59 indicates that AGFB is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.59, AGFB is in line with its industry, outperforming 45.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF N/A
Altman-Z 2.15
ROIC/WACCN/A
WACC8.81%
AGFB.BR Yearly LT Debt VS Equity VS FCFAGFB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.99 indicates that AGFB should not have too much problems paying its short term obligations.
With an excellent Current ratio value of 1.99, AGFB belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
A Quick Ratio of 1.14 indicates that AGFB should not have too much problems paying its short term obligations.
AGFB has a Quick ratio of 1.14. This is comparable to the rest of the industry: AGFB outperforms 54.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.14
AGFB.BR Yearly Current Assets VS Current LiabilitesAGFB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

3

3. Growth

3.1 Past

AGFB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -57.63%.
The Revenue has decreased by 0.00% in the past year.
AGFB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.44% yearly.
EPS 1Y (TTM)-57.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.5%
Revenue 1Y (TTM)0%
Revenue growth 3Y-13.53%
Revenue growth 5Y-10.44%
Sales Q2Q%-3.2%

3.2 Future

The Earnings Per Share is expected to grow by 56.83% on average over the next years. This is a very strong growth
AGFB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.91% yearly.
EPS Next Y128.57%
EPS Next 2Y77.28%
EPS Next 3Y56.83%
EPS Next 5YN/A
Revenue Next Year1.11%
Revenue Next 2Y2.16%
Revenue Next 3Y2.35%
Revenue Next 5Y0.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AGFB.BR Yearly Revenue VS EstimatesAGFB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B 2B 2.5B
AGFB.BR Yearly EPS VS EstimatesAGFB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

AGFB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
AGFB is valuated reasonably with a Price/Forward Earnings ratio of 8.03.
100.00% of the companies in the same industry are more expensive than AGFB, based on the Price/Forward Earnings ratio.
AGFB is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.69, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 8.03
AGFB.BR Price Earnings VS Forward Price EarningsAGFB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGFB.BR Per share dataAGFB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AGFB's earnings are expected to grow with 56.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y77.28%
EPS Next 3Y56.83%

More info and screens

0

5. Dividend

5.1 Amount

AGFB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGFA-GEVAERT NV

EBR:AGFB (9/5/2025, 7:00:00 PM)

0.983

-0.03 (-3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-27 2025-08-27
Earnings (Next)11-13 2025-11-13
Inst Owners51.57%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap152.19M
Analysts75.56
Price Target1.22 (24.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.85%
PT rev (3m)2.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)125.06%
EPS NY rev (3m)125.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.03
P/S 0.13
P/FCF N/A
P/OCF 76.09
P/B 0.52
P/tB 2.93
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)0.12
Fwd EY12.45%
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)0.01
OCFY1.31%
SpS7.3
BVpS1.89
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.69%
ROE -31.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.24%
FCFM N/A
ROA(3y)-8.91%
ROA(5y)0.06%
ROE(3y)-32.3%
ROE(5y)1.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.64%
OM growth 5Y-16.64%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.88%
F-Score4
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 104.88%
Cap/Sales 3.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.14
Altman-Z 2.15
F-Score4
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)78.36%
Cap/Depr(5y)64.97%
Cap/Sales(3y)3.26%
Cap/Sales(5y)2.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.5%
EPS Next Y128.57%
EPS Next 2Y77.28%
EPS Next 3Y56.83%
EPS Next 5YN/A
Revenue 1Y (TTM)0%
Revenue growth 3Y-13.53%
Revenue growth 5Y-10.44%
Sales Q2Q%-3.2%
Revenue Next Year1.11%
Revenue Next 2Y2.16%
Revenue Next 3Y2.35%
Revenue Next 5Y0.91%
EBIT growth 1Y-327.27%
EBIT growth 3Y-14.94%
EBIT growth 5Y-25.35%
EBIT Next Year235.3%
EBIT Next 3Y67.32%
EBIT Next 5Y48.33%
FCF growth 1Y68.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.04%
OCF growth 3YN/A
OCF growth 5YN/A